FDA Grants Priority Review to Intellia’s CRISPR-Based HAE Therapy
Event summary
- FDA accepted Intellia’s BLA for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.
- Lonvo-z, if approved, would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
- Phase 3 HAELO trial showed an 87% reduction in mean monthly attacks for lonvo-z compared with placebo.
- Lonvo-z received multiple regulatory designations, including Orphan Drug, RMAT, Innovation Passport, PRIME, and ODD.
The big picture
Intellia’s lonvo-z represents a significant step forward in the application of CRISPR technology for rare genetic diseases. The FDA’s Priority Review underscores the potential of this one-time treatment to transform the management of HAE, positioning Intellia at the forefront of gene-editing therapeutics. Success here could validate the broader viability of in vivo CRISPR therapies, attracting further investment and partnerships in the biotech sector.
What we're watching
- Regulatory Pathway
- Whether the FDA’s Priority Review will lead to a timely approval of lonvo-z by the March 2027 PDUFA date.
- Commercialization Readiness
- How Intellia prepares for the potential launch of lonvo-z, given its status as a one-time treatment for a rare disease.
- Market Impact
- The potential shift in the HAE treatment landscape if lonvo-z becomes the first approved in vivo CRISPR-based therapy.